QBS72S, a LAT1-targeted agent, shows potential in treating leptomeningeal disease, improving survival rates in metastatic ...

LP-184 shows promising efficacy and safety in heavily pretreated advanced cancer patients, paving the way for innovative ...

JANX007 shows significant PSA reductions and favorable rPFS in mCRPC patients, with a manageable safety profile. The trial identifies 6 mg and 9 mg as optimal doses, balancing safety and efficacy.

As Dr Voorhees mentioned in part 2, the definition of high-risk SMM has evolved over time and is subject to change in the ...

IGV-001, an investigational autologous cell immunotherapeutic combination product, may offer clinically meaningful overall ...

The FDA has granted traditional approval to pirtobrutinib (Jaypirca) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma ...

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.

Dr. Peter Voorhees discusses groundbreaking AQUILA study results, highlighting daratumumab's significant impact on high-risk ...

Sacituzumab tirumotecan demonstrated a 31% objective response rate and 71% disease control rate in advanced urothelial ...

The 2025 American Society of Hematology (ASH) Meeting and Exposition in Orlando, Florida, begins on December 6. This year, ...

Naxitamab plus GM-CSF demonstrated strong antitumor activity and manageable toxicity in high-risk neuroblastoma patients, ...

Sequential ICV and IV administration of CR7-GD2 CAR T-cell therapy showed improved tolerability over concurrent dosing in ...